← FDA DRUG APPROVALS

FDA ANDA · ANDA074940

CLONAZEPAM

Sponsor: QUAGEN

APPLICATION
ANDA074940
TYPE
ANDA
ORIGINAL APPROVAL
1997-10-30
LATEST ACTION
2024-08-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

CLONAZEPAMDiscontinued
CLONAZEPAM 1MG · TABLET · ORAL
CLONAZEPAMDiscontinued
CLONAZEPAM 2MG · TABLET · ORAL
CLONAZEPAMDiscontinued
CLONAZEPAM 0.5MG · TABLET · ORAL

Approval history

2024-08-28Labeling · Supplement 7 · standardAP
2015-11-03Labeling · Supplement 6AP
2009-10-15Labeling · Supplement 5AP
2002-02-26Labeling · Supplement 3AP
2000-12-15Labeling · Supplement 2AP
1998-10-26Labeling · Supplement 1AP
1997-10-30OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →